Infectious Diseases

Back to articles

Bezlotoxumab effective for prevention of recurrent C. difficile infections

KEY POINT

Use of bezlotoxumab (Zinplava—Merck) was found to be effective and safe at reducing the rate of recurrent Clostridium difficile infection in adult patients receiving standard oral antibiotics for primary or recurrent C. difficile infections, according to results of the MODIFY I and II trials published in the New England Journal of Medicine.

SOURCES

Wilcox MH, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile Infection. N Engl J Med. 2017;376(4):305–17.

Bartlett, JG. Bezlotoxumab—A new agent for Clostridium difficile infection. N Engl J Med. 2017;376(4):381–2.